## DHR: Danaher Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 0.8% below STRENGTH zone (4.0-10.0%); PEG 1.85 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-5.1% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($216.41)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Danaher Corporation (DHR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation**
- Source: MyStateline | 20251130T110000 | Neutral | Relevance: 99%
- Bronstein, Gewirtz & Grossman, LLC has initiated an investigation into Danaher Corporation (NYSE: DHR) on behalf of stockholders who purchased securities prior to April 21, 2022, and continue to hold them. The investigation aims to determine if Danaher and its officers/directors engaged in corporate wrongdoing. The firm encourages affected investors to contact them to learn more and assist with the investigation, emphasizing that there is no cost to the investors involved.

**2. Loomis Sayles & Co. L P Grows Holdings in Danaher Corporation $DHR**
- Source: MarketBeat | 20251130T050000 | Somewhat-Bullish | Relevance: 99%
- Loomis Sayles & Co. L P increased its stake in Danaher Corporation (NYSE:DHR) by 0.2%, now owning 764,495 shares valued at $151.02 million. Danaher reported strong Q3 earnings, beating estimates with $1.89 EPS on $6.05 billion revenue, and analysts maintain a "Moderate Buy" rating with an average target price of $243.39. Despite recent insider selling, institutional investors hold a significant 79.05% of the company's stock, and Danaher pays a quarterly dividend of $0.32.

**3. Bronstein, Gewirtz & Grossman, LLC Encourages Danaher Corporation (DHR) Stockholders to Inquire about Securities Investigation**
- Source: WJBF | 20251202T110000 | Neutral | Relevance: 99%
- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Danaher Corporation (NYSE: DHR) securities who bought prior to April 21, 2022, and still hold them. The investigation focuses on whether Danaher and its officers engaged in corporate wrongdoing. The firm encourages affected investors to assist the investigation through its website or by contacting its representatives.

**4. Bronstein, Gewirtz & Grossman, LLC Encourages Danaher Corporation (DHR) Stockholders to Inquire about Securities Investigation**
- Source: ABC4 Utah | 20251202T110000 | Neutral | Relevance: 99%
- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Danaher Corporation (NYSE:DHR) securities. The investigation focuses on whether Danaher and its officers engaged in corporate wrongdoing, targeting investors who bought shares prior to April 21, 2022, and continue to hold them. The firm encourages affected stockholders to contact them to assist with the investigation.

**5. J.W. Cole Advisors Inc. Purchases 1,569 Shares of Danaher Corporation $DHR**
- Source: MarketBeat | 20251202T110422 | Somewhat-Bullish | Relevance: 99%
- J.W. Cole Advisors Inc. increased its stake in Danaher Corporation by 54.9%, acquiring an additional 1,569 shares, bringing their total holdings to 4,429 shares valued at $875,000. This increase comes alongside significant insider selling from Danaher SVPs, who collectively sold over 30,000 shares worth approximately $6.61 million in the last three months. Danaher reported strong quarterly earnings, beating analyst estimates, and maintains a "Moderate Buy" consensus rating with a target price of $243.39.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Goldman Sachs | $265 | $0 | 0% |
| 2025-12-02 | Morgan Stanley | $270 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Goldman Sachs | init | Buy |
| 2025-12-02 | Morgan Stanley | init | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 8 ($0.20M) |
| Sells | 10 ($75.99M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 37.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 8.6% (+0.2%)
- Blackrock Inc.: 7.4% (+0.1%)
- JPMORGAN CHASE & CO: 5.3% (+404.7%)
- State Street Corpora: 3.9% (-0.3%)
- Capital Internationa: 2.4% (+1.9%)

### Key Risks

1. Heavy insider selling: $76M sold (10 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.85 elevated, pricing in significant growth expectations. Forward P/E 26.9x stretched relative to 9% growth. Balance sheet: $1.4B free cash flow. Insider selling cluster ($76.0M in 90 days), potential headwind. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $165.0B |
| Beta | 0.92 |
| 52W Range | $171.00 - $258.23 |
| Short Interest | 1.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.85 |
| Forward P/E | 26.9 |
| Current P/E | 29.4 |
| YoY Growth | 9.2% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 5.9% to 0.8% (-5.1% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 3.2pp (needs >4.0% for momentum thesis). MRS_5 (-1.0%) diverging from MRS_20 - short-term weakness emerging. Full SMA alignment bullish (above 20/50/200 SMAs).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.80% (CS: 68) | Neutral |
| RSI_14 | 60.1 | Neutral |
| MACD Histogram | 0.01 | Bullish |
| vs SMA20 | 1.026x | Above |
| vs SMA50 | 1.065x | Above |
| vs SMA200 | 1.118x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $226.59
- **Stop Loss:** $216.41 (4.5% risk)
- **Target:** $236.77 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 98
- **Position Value:** $22,205.82
- **Portfolio %:** 22.21%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate improvement trajectory. VIX compression from 20.5 to 16.6 over 5 days signals declining fear, while 47% breadth shows narrow but recovering participation. Fed meeting in 6 days creates near-term uncertainty, but AI sector momentum and improving technical setups support selective positioning.*

### Earnings

**Next:** 2026-01-28 (Est: $2.14)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.72 | $1.89 | +9.8% |
| 2025Q2 | $1.64 | $1.80 | +9.5% |
| 2025Q1 | $1.64 | $1.88 | +14.4% |
| 2024Q4 | $2.16 | $2.14 | -1.1% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*